{"id":"NCT01162122","sponsor":"Novartis Vaccines","briefTitle":"Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects","officialTitle":"A Phase III, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety and Immunogenicity and the Consistency of Three Consecutive Lots of a MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects Aged 65 Years and Older","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-08","primaryCompletion":"2011-08","completion":"2011-11","firstPosted":"2010-07-14","resultsPosted":"2014-06-12","lastUpdate":"2014-06-26"},"enrollment":7109,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"PREVENTION"},"conditions":["Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"MF59 adjuvanted trivalent subunit influenza vaccine (aTIV)","otherNames":["Fluad"]},{"type":"BIOLOGICAL","name":"Non-adjuvanted trivalent subunit influenza vaccine (TIV)","otherNames":["Agriflu"]}],"arms":[{"label":"aTIV","type":"EXPERIMENTAL"},{"label":"Licensed TIV","type":"EXPERIMENTAL"}],"summary":"The present phase III study aims to evaluate the safety and immunogenicity of MF59-adjuvanted subunit seasonal influenza vaccine and to evaluate the consistency in the manufacturing process of three consecutive lots of MF59-adjuvanted subunit seasonal influenza vaccine with respect to immunogenicity in subjects aged 65 years and older. The active comparator non-adjuvanted seasonal influenza vaccine is approved for use in this age group in the United States and will be used to provide a comparative assessment for immunogenicity and safety.","primaryOutcome":{"measure":"Geometric Mean Titers in Subjects After Receiving One Dose of Lot 1 or Lot 2 or Lot 3 of aTIV","timeFrame":"Day 22 post vaccination","effectByArm":[{"arm":"aTIV_Lot 1","deltaMin":209,"sd":null},{"arm":"aTIV_Lot 2","deltaMin":187,"sd":null},{"arm":"aTIV_Lot 3","deltaMin":199,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null}]},"eligibility":{"minAge":"65 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":38,"countries":["United States","Colombia","Panama","Philippines"]},"refs":{"pmids":["25045825"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":264,"n":3545},"commonTop":["Injection site pain","Headache","Myalgia","Fatigue","Arthralgia"]}}